The combination of nuclear and mitochondrial mutations as a risk factor for idiosyncratic toxicity
- 1 February 2007
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 63 (2) , 249-251
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- A study to survey susceptible genetic factors responsible for troglitazone‐associated hepatotoxicity in Japanese patients with type 2 diabetes mellitusClinical Pharmacology & Therapeutics, 2003
- Idiosyncratic drug reactions: the reactive metabolite syndromesThe Lancet, 2000
- Advances in molecular toxicology–towards understanding idiosyncratic drug toxicityToxicology, 2000
- Combined glutathione-S -transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicityClinical Pharmacology & Therapeutics, 2000
- Titrating the Effects of Mitochondrial Complex I Impairment in the Cell PhysiologyJournal of Biological Chemistry, 1999
- New Concepts in Immunology Relevant to Idiosyncratic Drug Reactions: The “Danger Hypothesis” and Innate Immune SystemChemical Research in Toxicology, 1999
- Elevation of Mitochondrial Transmembrane Potential and Reactive Oxygen Intermediate Levels Are Early Events and Occur Independently from Activation of Caspases in Fas SignalingThe Journal of Immunology, 1999
- Comparisons of Oxidative Metabolism and Reductive Capacity in Sulfonamide-Tolerant and -Intolerant Patients with Human Immunodeficiency VirusThe Journal of Clinical Pharmacology, 1996
- Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacksPharmacogenetics, 1996
- The Glut athione S-Transferase Supergene Family: Regulation of GST and the Contribution of the lsoenzymes to Cancer Chemoprotection and Drug Resistance Part ICritical Reviews in Biochemistry and Molecular Biology, 1995